News

Precision Medicine Online1h
FDA Approves Abeona's Zevaskyn, EC Authorizes Krystal's Zevaskyn for Rare Skin Disease
Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.
BioPharma Dive2h
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
American Academy of Dermatology2h
Sun exposure taking a toll: new AAD survey shows sharp increase in sun damage across the U.S.
ROSEMONT, Ill. (April 29, 2025) — A recent survey of more than 1,000 U.S. adults showed that nearly all Americans believe sun protection is important, with 1 in 4 citing the influence of a ...
BioSpace3h
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
Healio3h
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...
Fierce Pharma3h
Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease
Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.
Soy Carmín on MSN5h
Smooth Moves: Dermatologists Reveal Their Top Tips for Managing (And Preventing) Crepey Skin
Crepey skin, characterized by its thin, wrinkled texture resembling crepe paper, is a common concern as we age. Fortunately, dermatologists have a wealth of knowledge on how to manage and even prevent ...